Company / Operating Margin
Ultragenyx Pharmaceutical Inc. Operating Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-79.5%
FY2025
5-year range
-409.0% / -79.5%
FY2021-FY2025
Trend
+16.9%
vs FY2024
Sector context
#81 of 136
Health Care
What the data says
At -79.5%, Ultragenyx Pharmaceutical Inc.'s operating margin ranks #81 of 136 in the Health Care sector. Operating Margin has increased for 6 consecutive years, from -12593.5% in FY2019 to -79.5% in FY2025.
Based on SEC 10-K filings.
-79.5% in FY2025 with a 5-year CAGR of +641.7%.
Improved from -131.1% to -79.5% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- +99.1pp
- 5-Year Change
- +641.7pp
- 10-Year Change
- -
Sector benchmark
#81 of 136 in Health CareTop 60% of 136This company -79.5% Sector average -778.9%
▼
+89.8% above sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s operating margin has grown for 6 consecutive years.
- In FY2025, operating margin increased 16.9% year-over-year.
- Currently 699.4pp above the Health Care sector average.
- Lowest operating margin in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -79.5% | +16.9% |
| FY2024 | -95.7% | +27.0% |
| FY2023 | -131.1% | +26.6% |
| FY2022 | -178.6% | +56.3% |
| FY2021 | -409.0% | +43.3% |
| FY2020 | -721.2% | +94.3% |
| FY2019 | -12593.5% | -1646.2% |
| FY2018 | -721.2% | +99.4% |
| FY2017 | -111081.2% | +66.7% |
| FY2016 | -333988.2% | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026